The global pharmaceuticals market is experiencing constant growth due to the worldwide increase in life expectancy, as well as the increasing incidence of chronic and infectious diseases. The steadily increasing demand for innovative drugs has thus t ....see more
The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021. Over the years, the sunitinib malate market for pancreatic cancer has observed steady growth and this trend is expected to continue in the coming years. This is primarily because the market is witnessing increasing adoption of drug therapy for the treatment of pancreatic cancer. This report categorizes patients with pancreatic neuroendocrine tumors (pNET) based on three different stages, namely, localized, advanced, and distant.
The global enteral feeding formulas market is estimated to reach USD 5.95 Billion by 2020, growing at a CAGR of 7.6% during the forecast period. The enteral feeding formulas market is mainly driven by the rising incidences of chronic diseases and disorders, the rapidly increasing geriatric population, increasing healthcare expenditure, rising prevalence of preterm births, and increasing demand for homecare.
Over the years, the European nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The European radiopharmaceuticals market is witnessing growth owing to an increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 radioisotopes are estimated to contribute the highest to the European nuclear medicine diagnostic market in 2015, whereas Ra-223, I-131 and Y-90 ensured their leading position in the therapeutic market. The European nuclear medicine/radiopharmaceuticals market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, growing at a CAGR of 8.2% from 2015 to 2020.
The global Wellness Supplements market is expected to reach USD 249.4 Billion by 2020 from USD 183.1 Billion in 2015, at a CAGR of 6.4% during the forecast period. The growth of wellness supplement is mainly driven by factors such as rising geriatric population, growing prevalence of chronic diseases, rising awareness about benefits of wellness supplements, rising healthcare costs, and shift of consumers from care to preventive. However, regulatory compliance is likely to restrain the growth of wellness supplement market to a certain extent.
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
Obesity and weight gain have always been major concerns regarding the health and fitness of individuals; today, it has reached the level of an epidemic. Increasing obesity rate and increasing levels of awareness amongst calorie-conscious consumers in North America have opened new avenues for the weight management industry.
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care. Autologous Stem Cell market is currently estimated as $650 million, including products of all application areas. This market is anticipated to reach $2.2 billion by 2017, growing at a CAGR of 21%. ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc.
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
This research report categorizes the Global Clinical Trials Market on the basis of phases, indications, and study design analyzing trends in each. Each section will provide market data, market drivers, trends and opportunities, key players, and competitive outlook. This report will also provide more than 20 company profiles.
Preterm infant care forms a significant part of the pediatric healthcare market in U.S as preterm births are on a alarming rise in the nation. Preterm births are one of the leading causes of infant mortality in U.S with 1 in 8 births being preterm. Induced fertility and labor treatments, poor prenatal care, inappropriate maternal age, obesity, smoking are some of the major reasons responsible for increasing incidence of preterm births in the country. Preterm infant care products such as infant care devices, infant formula and drugs face a great demand in United States due to the absolute necessity of such products in sustaining baby lives. The products are indispensable in saving preterm babies because they are biologically immature and require external medical assistance in the form of respiratory, nutritional and thermal control support for survival. Infant care products have helped to increase the survival of preterm babies in the country. The criticality of the products in preterm infant care is driving the market. Furthermore, technology advances in regards to multi function equipments are also propelling the growth of the market.
Obesity and weight gain issues have always been major concerns impacting the health and fitness of the individuals. Increasing levels of awareness amongst the calorie conscious consumers have opened up new avenues and opportunities in this market.
The global anesthesia and respiratory devices market is expected to witness moderate growth in the coming five years. Respiratory devices account for the largest share (about 57%) in this market; primarily due to their wide usage among the three consumer segments (healthcare institutions, home healthcare and transport) as compared to anesthesia devices; which have limited usage amongst the end-users.
The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. The growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecasted to grow at a compound annual growth rate (CAGR) of 11.2%.
Increasing number of web users’ world wide (1.8 billion), development and popularity of web based community sites (Twitter, Facebook), tools and information centers (branded & unbranded sponsored communities) are changing approach towards Pharma and healthcare marketing and information sharing. In pharma industry social media has emerged as an effective tool for marketing, consumer engagement, monitoring & analyzing user generated content and building & changing brand perception. Social media is emerging as a strategic shift in organizations communication and operation model. Top pharmaceutical market players have started integrating social media in to their marketing mix. The effective social media marketing strategies that can help generate business exposure, market research data, relationship building and thus can prove as an important initiative to boom sales and overall business in the long term
The prevalence of diabetes is increasing globally with the increase in life expectancy and rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated over 20 million patients in the region requiring diabetes treatment by 2025. India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.
The increase in public awareness and government initiatives, as a consequence of scare from pandemic flu has resulted in the drastic rise in demand for the Influenza Vaccines. This transient boost in demand of seasonal influenza vaccines is an impact of prevailing H1N1 pandemic, due to apprehension and lack of clarity among the general public. The emerging technologies in production are going to give a new face to the market dynamics of this market. The upcoming vaccines and drugs by various players in the market such as Novartis’ Optaflu and ProteinSciences’ FluBlock, along with the emerging technologies in production are going to give a new face to the market dynamics of this market.
The report sizes the market for the diagnosis and therapeutic technologies for the auto immune diseases. It also tracks the advances in the technologies along with the profiles and strategies of the key players in this market. The report highlights the new approaches being pursued in this market.
Obesity and weight gain issues have always been a major concern impacting the health and fitness of the individuals. Increasing awareness levels among the appearance and calorie conscious consumers has opened up new avenues and opportunities to this market. The rate of new product entry in the weight management segment is significantly high, necessitating industry participants to adopt proactive strategies and keep ahead of competition.